profit from every CA$100 of sales.
CA$0CA$100
Extendicare
CA$30.34+0.83% today
+102.7% in 1 year
1-year low CA$14.971-year high CA$38.79
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average.
0%20% a year
You pay CA$29.83 for every CA$1 of profit it makes in a year.
CheapExpensive
It holds more cash than debt.
No debt5 years
Extendicare vs. similar companies
Extendicare grows in the middle of these 5 and is priced in the middle for its profits.
| Company | Profit from CA$100 of sales | Sales growth a year | Price per CA$1 of profit |
|---|---|---|---|
| Extendicare | 29.8× · Fair price | ||
 HCA Healthcare | 15.4× · Fair price | ||
 Fresenius SE & Co. KGaA | 23.9× · Fair price | ||
 IHH Healthcare Berhad | 34.3× · Expensive | ||
 Rede D'Or São Luiz | 16.2× · Fair price |
AI analysis
An AI analyst reads Extendicare's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisNo annual statements on file yet.
Valuation
- 29.8×
- –
- 1.76
- 8.3×
- 1.7×
- 27.8×
- –
- 3.6%
- 3.4%
- –
Profitability
- –
- 8.4%
- 5.8%
- –
- 15.6%
- 12.8%
- –
- –
- –
- –
Growth
- +10.8%
- +17.0%
- –
- –
- −4.6%
Financial health
- -0.1×
- 0.88
- –
- 7.7×
- 1.37
- –
- –
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Top 14%of 964
Bottom 42%of 898
Bottom 46%of 651
Top 49%of 911
Top 33%of 991
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
50No pass
Benjamin Graham
40No pass
Philip Fisher
59No pass
Peter Lynch
52No pass
Joel Greenblatt
29No pass
Charlie Munger
51No pass
Terry Smith
51No pass
Questions about Extendicare
Is Extendicare a good stock to buy?
A business with weak numbers at a fair price. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Extendicare AI analysis
What does Extendicare do?
Extendicare Inc., through its subsidiaries, provides care and services for seniors in Canada. It operates through the Long-term Care, Home Health Care, and Managed Services segments. It is in Medical Care Facilities.
Is Extendicare stock halal?
Yes. Extendicare passes our halal screen: its business is permitted and its debt is 11% of its market value, under the 30% limit. How we check
How has Extendicare stock done over the past year?
Up 102.7% over the past twelve months, to CA$30.34. It traded between CA$14.97 and CA$38.79 and is 21.8% below its high.
Who are Extendicare's competitors?
The largest listed companies in the same industry are HCA Healthcare, Fresenius SE & Co. KGaA, IHH Healthcare Berhad and Rede D'Or São Luiz. The peers table on this page compares their profit, growth and price with Extendicare's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.